Literature DB >> 11324461

Behavioral characteristics of olanzapine: an atypical neuroleptic.

Y Fu1, Z T Zhu, L J Chen, L P Yu, G Z Jin.   

Abstract

AIM: To assess the atypical neuroleptic properties of a novel antipsychotic agent, olanzapine (Ola).
METHODS: The action of Ola on apomorpine (Apo)-induced climbing behavior, 5-hydroxy-dl-tryptophan (5-HTP)-induced head twitch response, oxotremorine-induced tremor, and the conditioned avoidance behavior in mice were observed. The catalepsy of mice induced by Ola was also investigated. The single unit extracellular recording technique was used to compare the spontaneous firing rate changes of dopamine (DA) cells in the ventral tegmental area (VTA, A10) and the substantia nigra pars compact (SNC, A9) in rats after i.v. Ola.
RESULTS: Ola antagonized the climbing behavior (ED50 1.8 mg.kg-1, p.o.), head twitch behavior (ED50 0.3 mg.kg-1, p.o.), and tremor (ED50 5.2 mg.kg-1, p.o.) in mice. In a conditioned avoidance paradigm in mice, Ola inhibited the avoidance response with an ED50 of 2.72 mg.kg-1 (p.o.). However, the catalepsy was not induced by Ola in mice even under a very high dose of 100 mg.kg-1 (p.o.). Ola selectively increased the firing rate of DA cells in the VTA, but failed to affect that of SNC DA cells.
CONCLUSION: Ola distinguished itself from the typical neuroleptic (e.g. haloperidol, Hal) and took resemblance of the atypical neuroleptic (e.g. clozapine, Clo) in 3 aspects: 1) the multiple receptor pharmacodynamics involving D1/D2, 5-HT2 and M-ACh receptors; 2) dose-response separation between the block of conditioned avoidance response and catalepsy induction; and 3) the specificity of action sites of firing rates upon acute drug challenge.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11324461

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

1.  Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Authors:  Ouissame Mnie-Filali; Céline Faure; Laura Lambás-Señas; Mostafa El Mansari; Hassina Belblidia; Elise Gondard; Adeline Etiévant; Hélène Scarna; Anne Didier; Anne Berod; Pierre Blier; Nasser Haddjeri
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

2.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

3.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

4.  GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.

Authors:  Elena Filatova; Anastasiya Kasian; Timur Kolomin; Ekaterina Rybalkina; Anelya Alieva; Lyudmila Andreeva; Svetlana Limborska; Nikolay Myasoedov; Galina Pavlova; Petr Slominsky; Maria Shadrina
Journal:  Front Pharmacol       Date:  2017-02-28       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.